TMEM37 and chronic myelogenous leukemia, BCR-ABL1 positive: Future studies with TCRGP armed with training data of TCRs against leukemia-associated antigens, such as WT1 and PR1, could provide crucial information on the antitumor immunity in patients with CML treated with different therapies.